Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins

Mol Cancer Ther (2015) 14 (11): 2441–2451.

https://doi.org/10.1158/1535-7163.MCT-15-0230

Published: 03 November 2015

View articletitled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Includes: Supplementary data

Journal Articles

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates ¹⁸F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

Heather Keen, Sally‐Ann Ricketts, Juliana Bales, Aoife Shannon, Armelle Logie, Rajesh Odedra, Steve Wedge, Sylvie Guichard

Mol Cancer Ther (2009) 8 (12_Supplement): A225.

https://doi.org/10.1158/1535-7163.TARG-09-A225

Published: 10 December 2009

View articletitled, Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

Journal Articles

AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy

Aoife Shannon, Brian Telfer, Muhammed Babur, Paul Smith, Armelle Logie, Robert Wilkinson, Ian Stratford, Kaye Williams, Steve Wedge

Mol Cancer Ther (2007) 6 (11_Supplement): A244.

Published: 01 November 2007

View articletitled, AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy

Journal Articles

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logie, Jennifer S. McKay, Paul Martin, Samantha Steele, Richard Jenkins, Mark Cockerill, Sue Cartlidge, Paul D. Smith

Mol Cancer Ther (2007) 6 (8): 2209–2219.

https://doi.org/10.1158/1535-7163.MCT-07-0231

Published: 15 August 2007

View articletitled, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates ¹⁸F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates ¹⁸F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

AACR Journals
on Social Media